Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effectiveness of Vorasidenib and Temozolomide for Patients with IDH1 or IDH2 Mutant Glioma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of brain tumor called glioma, which has specific genetic changes known as IDH1 or IDH2 mutations. The study will test a combination of two treatments: vorasidenib and temozolomide. Vorasidenib is a new medication being tested, while temozolomide is a chemotherapy drug already used to treat brain tumors. The purpose of the study is to evaluate how safe and tolerable vorasidenib is when used with temozolomide and to see how effective this combination is in treating gliomas with these mutations.

Participants in the study will receive the medications in the form of capsules or tablets taken by mouth. The study will be conducted in two phases. In the first phase, the focus will be on determining the best dose of vorasidenib to use with temozolomide. In the second phase, the study will look at how well the combination works in controlling the tumor over a period of time. The study will also monitor the participants for any side effects or adverse reactions to the treatment.

The study aims to gather information on the progression of the disease and the overall survival of participants. It will also measure the levels of vorasidenib and its breakdown products in the blood, as well as the levels of temozolomide. The study is expected to continue until early 2028, with recruitment of participants starting in 2025. This research is important for understanding how these treatments can be used together to potentially improve outcomes for patients with IDH1 or IDH2 mutant gliomas.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment will be conducted to confirm eligibility. This includes verifying age, weight, and medical history related to IDH1 or IDH2-mutant glioma.

    Blood tests will be performed to check liver, kidney, and bone marrow function. A pregnancy test is required for female participants of reproductive potential.

  2. Step 2

    Treatment initiation

    The treatment phase begins with the administration of two medications: vorasidenib and temozolomide.

    Vorasidenib is taken orally in the form of film-coated tablets. The dosage and frequency will be determined by the study team.

    Temozolomide is taken orally as hard capsules. The dosage and frequency will be specified by the study team.

  3. Step 3

    Treatment monitoring

    Regular monitoring will occur throughout the treatment period to assess safety and tolerability. This includes checking for any side effects or adverse reactions.

    Blood tests and other assessments will be conducted periodically to monitor the body's response to the treatment.

  4. Step 4

    Follow-up assessments

    Follow-up assessments will be conducted to evaluate the effectiveness of the treatment. This includes measuring progression-free survival, which is the length of time during and after treatment that the disease does not worsen.

    Additional tests may be performed to gather information on the concentration of the medications in the blood and their effects.

  5. Step 5

    Completion of study

    Upon completion of the study, a final assessment will be conducted to gather data on the overall outcomes and any long-term effects of the treatment.

    Participants will be informed of the study results and any further steps, if necessary.

Who can join the trial?

15 criteria

  • Be at least 18 years old and weigh at least 40 kg.
  • Phase 1b ONLY: Have a confirmed diagnosis of Grade 2, 3, or 4 IDHm glioma, which is a type of brain tumor. For oligodendroglioma, there must be a specific genetic change called 1p19q co-deletion. For astrocytoma, there should be no 1p19q co-deletion and/or a change in the ATRX gene.
  • Phase 1b ONLY: Be suitable to receive TMZ (a type of chemotherapy) after radiotherapy or for the first recurrence of the disease, as judged by the doctor. If receiving TMZ after radiotherapy, treatment must start within 6 weeks after finishing radiotherapy.
  • Have good liver function, shown by specific blood test results: total bilirubin ≤1.5 times the normal limit, AST and ALT (liver enzymes) within normal limits, and alkaline phosphatase ≤2.5 times the normal limit.
  • Phase 2 ONLY: Have a confirmed diagnosis of Grade 4 astrocytoma, IDHm. Those with a specific genetic deletion called CDKN2A/B are eligible.
  • Phase 2 ONLY: Have no 1p19q co-deletion and/or a change in the ATRX gene, confirmed by local testing.
  • Phase 2 ONLY: Have received standard radiotherapy with concurrent TMZ before joining the study. Treatment must start within 6 weeks after completing this therapy.
  • Have a documented IDH1 or IDH2 mutation, confirmed by testing of tumor tissue.
  • Have good kidney function, defined as a creatinine clearance of at least 40 mL/min, which is a measure of how well the kidneys are working.
  • Have good bone marrow function, shown by specific blood test results: absolute neutrophil count ≥1,500/mm³, hemoglobin ≥9 g/dL, and platelets ≥100,000/mm³.
  • Have recovered from any significant side effects of previous cancer treatments, unless they are stable and manageable according to the doctor.
  • Have an expected survival of at least 3 months.
  • Have a Karnofsky Performance Status (KPS) of at least 70, which is a measure of the ability to carry out daily activities.
  • If taking corticosteroids (a type of medication) for glioma-related reasons, the dose must be stable or decreasing (no more than 4 mg/day of dexamethasone or equivalent) for at least 5 days before starting the study treatment.
  • Female participants who can have children must have a negative pregnancy test before starting the study treatment. This includes women who have started menstruating and have not had surgery to remove the uterus or ovaries, and are not naturally postmenopausal (have not had a period for 24 consecutive months).

Who cannot join the trial?

10 criteria

  • Patients with any other type of cancer besides IDH1-mutant Glioma or IDH2-mutant Glioma cannot participate.
  • Patients who have had a recent heart attack or have severe heart problems are not eligible.
  • Patients with uncontrolled high blood pressure cannot join the study.
  • Patients who are pregnant or breastfeeding are not allowed to participate.
  • Patients who have an active infection that requires treatment with antibiotics are excluded.
  • Patients who have had another investigational drug within the last 4 weeks cannot participate.
  • Patients with a history of allergic reactions to similar drugs are not eligible.
  • Patients who have a condition that affects their ability to absorb medications in the stomach or intestines cannot join the study.
  • Patients with severe liver or kidney disease are excluded from the trial.
  • Patients who have a history of drug or alcohol abuse within the past year are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Vorasidenib

    is a medication being studied for its potential to help treat a type of brain tumor called glioma, which has specific genetic changes known as IDH1 or IDH2 mutations. In this clinical trial, vorasidenib is being tested to see if it can be safely used together with another medication to improve treatment outcomes. The goal is to find out if this combination can help control the growth of the tumor and improve the patient's condition.

  • Temozolomide (TMZ)

    is a well-known chemotherapy drug used to treat certain types of brain tumors. It works by damaging the DNA of cancer cells, which can stop them from growing and dividing. In this study, temozolomide is being used in combination with vorasidenib to see if the two medications together can be more effective in treating glioma with IDH1 or IDH2 mutations than temozolomide alone. The researchers are looking to see if this combination can help slow down the progression of the disease and improve survival rates for patients.

What is already known about the treatment

Vorasidenib – Vorasidenib is taken orally and is currently being studied in combination with another drug called temozolomide for treating a type of brain tumor known as glioma, specifically those with IDH1 or IDH2 mutations. This medication is still in the research phase, and scientists are evaluating its safety and effectiveness. Vorasidenib works by targeting specific mutations in the tumor cells, which may help slow down or stop the growth of the cancer. It is classified as a targeted therapy, which means it aims to attack cancer cells more precisely than traditional chemotherapy.

Investigated diseases

  • IDH1-mutant Glioma

    IDH1-mutant glioma is a type of brain tumor characterized by a mutation in the isocitrate dehydrogenase 1 (IDH1) gene. This mutation leads to abnormal cell growth in the brain, forming a mass that can disrupt normal brain function. The disease typically progresses slowly, with tumor cells infiltrating surrounding brain tissue. Over time, the tumor may increase in size, causing symptoms such as headaches, seizures, and cognitive changes. The progression can vary, with some tumors remaining stable for extended periods. As the tumor grows, it can exert pressure on the brain, leading to more pronounced neurological symptoms.

  • IDH2-mutant Glioma

    IDH2-mutant glioma is a brain tumor associated with a mutation in the isocitrate dehydrogenase 2 (IDH2) gene. This genetic alteration results in the uncontrolled proliferation of glial cells in the brain. The tumor typically grows slowly, infiltrating nearby brain tissue and potentially causing neurological symptoms. As the disease progresses, the tumor may enlarge, leading to increased intracranial pressure and associated symptoms such as headaches and seizures. The rate of progression can vary, with some tumors remaining indolent for years. Over time, the tumor's growth can lead to significant disruption of normal brain function.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-513738-39-00Protocol codeS095032-211Estimated enrolment50 patientsSponsorInstitut De Recherches Internationales Servier IRIS

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.